



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION  
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

<p>(51) International Patent Classification<sup>6</sup> : A61K 47/48, 48/00, 41/00, C12N 15/62</p>	<p>A3</p>	<p>(11) International Publication Number: <b>WO 95/24928</b> (43) International Publication Date: 21 September 1995 (21.09.95)</p>
<p>(21) International Application Number: PCT/US95/03448 (22) International Filing Date: 15 March 1995 (15.03.95) (30) Priority Data: 08/213,446 15 March 1994 (15.03.94) US 08/213,447 15 March 1994 (15.03.94) US (71) Applicant: PRIZM PHARMACEUTICALS, INC. [US/US]; 11035 Roselle Street, San Diego, CA 92121-1204 (US). (72) Inventors: SOSNOWSKI, Barbara, A.; 1013 Adella Avenue, Coronado, CA 92118 (US). BAIRD, J., Andrew; 5039 Via Papel, San Diego, CA 92118 (US). HOUSTON, L., L.; 327 Pine Needles Drive, Del Mar, CA 92014 (US). NOVA, Michael, P.; 8263 Camino Del Oro #476, San Diego, CA 92037 (US). (74) Agents: NOTTENBURG, Carol et al.; Seed and Berry, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104- 7092 (US).</p>		<p>(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG).  Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i> (88) Date of publication of the international search report: 12 October 1995 (12.10.95)</p>
<p>(54) Title: HEPARIN-BINDING GROWTH FACTORS FOR GENE THERAPY AND ANTERIOR EYE DISORDERS (57) Abstract  Preparations of conjugates of a heparin-binding growth factor and a targeted agent and compositions containing such preparations are provided. The conjugates contain a polypeptide that is reactive with an FGF receptor, such as bFGF, or another heparin-binding growth factor coupled to a targeted agent through a linker. The linker is selected to increase the specificity, toxicity, solubility, serum stability, and/or intracellular availability of the targeted moiety. Several linkers may be included in order to take advantage of desired properties of each linker. Pharmaceutical compositions containing these conjugates of FGF and a targeted agent and methods for prevention of recurrence of pterygii, closure of trabeculectomy and corneal hazing following excimer laser surgery are provided. The methods entail contacting the area of the eye that has been surgically treated with the composition during or immediately after surgery. Compositions of conjugates of a heparin-binding growth factor and a nucleic acid binding domain are provided. The conjugates bind nucleic acid molecules through the nucleic acid binding domain. These conjugates may be used to deliver nucleic acid encoding a cytotoxic protein or an antisense nucleic acid and the like to cells expressing receptors for the heparin-binding growth factor.</p>		

**FOR THE PURPOSES OF INFORMATION ONLY**

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

# INTERNATIONAL SEARCH REPORT

Internat. Application No.  
PCT/US 95/03448

A. CLASSIFICATION OF SUBJECT MATTER  
IPC 6 A61K47/48 A61K48/00 A61K41/00 C12N15/62

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)  
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
P, X	WO-A-95 03831 (PRIZM PHARMA INC ; WHITTIER INST FOR DIABETES AND (US)) 9 February 1995 cited in the application see claims ---	1
Y	BIOCONJUGATE CHEMISTRY, vol. 3, 1992 WASHINGTON US, pages 375-381, MICHAEL WESTBY ET AL. 'SEPARATION AND CHARACTERIZATION OF RECOMBINANT PRORICIN CONTAINING AN ALTERNATIVE PROTEASE-SENSITIVE LINKER SEQUENCE.' see the whole document --- -/-	1-4, 7-10, 12, 13, 21, 34, 36, 37, 71, 75

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

### \* Special categories of cited documents :

- \*A\* document defining the general state of the art which is not considered to be of particular relevance
- \*E\* earlier document but published on or after the international filing date
- \*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- \*O\* document referring to an oral disclosure, use, exhibition or other means
- \*P\* document published prior to the international filing date but later than the priority date claimed

- \*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- \*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- \*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- \*A\* document member of the same patent family

Date of the actual completion of the international search

10 August 1995

Date of mailing of the international search report

11.09.95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+ 31-70) 340-3016

Authorized officer

Berte, M

## INTERNATIONAL SEARCH REPORT

 Internat Application No  
 PCT/US 95/03448

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X,Y	<p>WO,A,91 18012 (BIOSPAN CORP) 28 November 1991</p> <p>see page 8, paragraph 2 - page 9, paragraph 2; tables I,II            see page 11, paragraph 2; claims            see page 10</p>	<p>1-4,            7-10,12,            13,21,            34,36,            37,71,75</p>
A	<p>---            CHEMICAL ABSTRACTS, vol. 116, no. 15,            13 April 1992            Columbus, Ohio, US;            abstract no. 149628,            FATTOM, A. ET AL 'Comparative            immunogenicity of conjugates composed of            the Staphylococcus aureus type 8 capsular            polysaccharide bound to carrier proteins            by adipic acid dihydrazide or            N-succinimidyl-3-(2-            pyridyldithio)propionate'            cited in the application            see abstract            &amp; INFECT. IMMUN. (1992), 60(2), 584-9            CODEN: INFIBR;ISSN: 0019-9567,            1992</p>	<p>1-3,9,10</p>
X	<p>---            WO,A,93 25688 (WHITTIER INST FOR DIABETES            AND ;PRIZM PHARMACEUTICALS INC (US); LA)            23 December 1993            cited in the application            see page 7, line 22 - line 27            see page 19, line 17 - line 27            see page 34, line 10 - page 35, line 25</p>	<p>1,18-33</p>
A	<p>---            WO,A,92 04918 (SALK INST FOR BIOLOGICAL            STUDI ;ROGER WILLIAMS GENERAL HOSPITA (US)            2 April 1992            cited in the application            see page 6, line 11 - line 34            see page 1, line 16 - line 22            see page 9, line 5 - line 29</p>	<p>38-52</p>
X	<p>---            WO,A,90 12597 (SALK INST FOR BIOLOGICAL            STUDI) 1 November 1990            cited in the application            see claims 1-10; example III            &amp; US,A,5 191 067</p> <p>---            -/--</p>	<p>38-52</p>

# INTERNATIONAL SEARCH REPORT

International Application No  
PCT/US 95/03448

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	<p>CHEMICAL ABSTRACTS, vol. 111, no. 1, 3 July 1989 Columbus, Ohio, US; abstract no. 1549, DAUCHEL, M. C. ET AL. 'Modulation of mitogenic activity and cellular binding of basic fibroblast growth factor by basic proteins' cited in the application see abstract &amp; J. CELL. BIOCHEM. (1989), 39(4), 411-20 CODEN: JCEBD5; ISSN: 0730-2312, 1989</p> <p style="text-align: center;">-----</p>	53,62,67

# INTERNATIONAL SEARCH REPORT

International application No.

PCT/US 95/03448

## Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This international search report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:  
because they relate to subject matter not required to be searched by this Authority, namely:  
Remark: Although claims 14-16, 35, 37, 42-52 are directed to a method of treatment of (diagnostic method practised on) the human/animal body the search has been carried out and based on the alleged effects of the compositions/compound.
2. ☒ Claims Nos.: 1, 53, 71  
because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out, specifically:  
please see enclosure
3. ☐ Claims Nos.:  
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

## Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims.
2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/SAJ/210

Incomplete Search

2. Obscurities, etc...

In view of the large number of compounds which are designed by the general formulas of claims 1,53,71 the search had to be restricted for economic reasons. The search was limited to the compounds for which pharmacological data was given and/or the compounds mentioned in the claims or examples (see PCT Search guidelines, Chapter III, paragraph 3.6).

# INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/03448

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-9503831	09-02-95	AU-B- 7475694	28-02-95
WO-A-9118012	28-11-91	US-A- 5169934	08-12-92
		CA-A- 2059649	15-11-91
		EP-A- 0482185	29-04-92
		JP-T- 5502886	20-05-93
		US-A- 5334391	02-08-94
WO-A-9325688	23-12-93	AU-B- 4635393	04-01-94
		CA-A- 2138038	23-12-93
		EP-A- 0646174	05-04-95
WO-A-9204918	02-04-92	CA-A- 2089820	20-03-92
		EP-A- 0552188	28-07-93
		JP-T- 6501005	27-01-94
WO-A-9012597	01-11-90	US-A- 5191067	02-03-93
		CA-A- 2053275	28-10-90
		DE-D- 69010330	04-08-94
		DE-T- 69010330	20-10-94
		EP-A- 0470183	12-02-92
		JP-T- 4507093	10-12-92